 Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
It’s official…
SpaceX is going public…
And they’re saying it could be anywhere from $800 billion…
To $1.5 TRILLION!
To date, the biggest IPO ever was Saudi Aramco… at a mere $25.6 billion.
That means… SpaceX’s IPO could be 58X BIGGER than the largest IPO in history. Wall Street insiders are salivating at this massive stock move.
But here’s the thing…
You do NOT have to be left out of this once-in-a-lifetime opportunity.
In fact, you can get action on this SpaceX IPO right now– before it goes public, in a regular brokerage account …
And you can get into this play for less than $100.
Click here for the full story.
It sounds nuts…
But this is your chance to beat Wall Street to the punch…
And get a piece of the action on the BIGGEST IPO in history…
Before the news even hits the market.
Do NOT miss this opportunity.
Click here to learn how to claim your stake NOW.
Best,
Matt Insley
Publisher, Paradigm Press
Exclusive Article Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They BoughtWritten by Thomas Hughes. Originally Published: 12/30/2025. 
What You Need to Know- Multiple leadership teams stepped in to buy in 2025—but the timing and pattern of those buys matter more than the headline count.
- One of the five names looks like a classic “insiders see value” setup, while another reads more like a risk tell than a green flag.
- The biggest 2026 decision point across the list isn’t insider activity—it’s whether a few specific catalysts break the right way.
Insider buying is an important metric for investors because it can indicate C-suite confidence in operations, growth, and profitability. Clustered insider buying—when multiple executives and directors buy around the same time—can be even more informative because it suggests shared conviction rather than a one-off trade. The goal isn’t simply to “buy because insiders bought.” Use 2025 insider activity as an initial screen, then determine whether each company has the fundamentals, catalysts, and valuation setup to be a smart 2026 watchlist candidate. Insiders Like Matador Resources Cash Flow, Growth, and Capital ReturnJust like Microsoft and Adobe rode the software wave in Web 1.0, RAD Intel is riding the AI software wave in 2025. Their product helps brands instantly find the right audience and message using AI – solving the #1 waste in marketing: misfired ad spend.
Already trusted by a who's-who of Fortune 1000 brands and leading global agencies – with recurring seven-figure partnerships in place. With a Nasdaq ticker reserved, $RADI, it's early – but very real. $0.85 Won't Last – Secure Your Shares Now. Matador Resources (NYSE: MTDR) is no stranger to InsiderTrades readers. It has ranked highly on insider-buying lists for years and was the top stock insiders bought in 2025. Fifteen insiders—including the CEO, COO, CAO, an EVP, and multiple directors—made more than 50 purchases in 2025, bringing their combined holdings to over 5% of the company. Drivers include Matador’s position in U.S. energy production, aggressive asset development, strong profitability, and shareholder capital return policy. The capital return is attractive, yielding more than 3.5% at year-end and appearing sustainable. The company pays less than 20% of earnings as dividends, which, together with its growth trajectory, supports aggressive annual increases. Matador often raises its payout more than once a year and has delivered a high double-digit distribution CAGR. Institutions own more than 90% of the stock and were net buyers in 2025, while analysts rate it a Moderate Buy with roughly 40%–50% upside potential. 
MicroStrategy’s Insider Activity Highlights Strategy RiskMicroStrategy (NASDAQ: MSTR) was the second-most-bought stock by insiders in 2025, with eight insiders buying in 21 transactions. However, those purchases were outweighed by far larger sales, pointing to a mass exodus from the stock. Contributing factors include the company’s persistent dilutive efforts to raise capital for BTC purchases, high debt and servicing costs, Bitcoin volatility, a reduced net asset value (NAV), and the potential for exclusion from major indices. Institutions that had been accumulating the shares reverted to selling in Q4, putting additional pressure on the stock into year-end. 
Shoulder Innovations Insiders Signal ConfidenceShoulder Innovations (NYSE: SI) is not a new company, although its history is spotty and it completed an IPO in 2025. The key takeaway: insiders—including the CEO, CFO, directors, and major shareholders—purchased shares after the IPO, signaling strong confidence and making it the third-most-bought stock by insiders. The company produces specialized, next-generation shoulder-replacement technology and is on track to sustain high-20% revenue growth over the next three to five years. Institutions, which own roughly 85% of the stock, have been accumulating, and analysts upgraded price targets in Q4. The consensus view is a Moderate Buy with about 35% upside. 
Smithfield Foods Insiders Buy Into Value and Growth OpportunitySmithfield Foods (NASDAQ: SFD) executives bought heavily in Q3 2025, putting the company in fourth place for insider buying that year. They increased positions around a secondary offering, signaling confidence in the growth trajectory and underscoring the value-and-yield opportunity. Trading at roughly a 10x earnings multiple, the stock sits well below consumer staples peers such as Hormel, implying it could rise materially on a valuation re-rating. The dividend yielded about 4.4% at year-end 2025 and is likely to rise over time. Institutions and corporate owners, which control roughly 98% of the stock, were net buyers in 2025, and analysts forecast double-digit upside in 2026. 
Rezolute, Inc. Fails to Pass Critical Hurdle Despite Insider ConfidenceRezolute, Inc. (NASDAQ: RZLT) is a late-stage biopharma focused on treatments for hyperinsulinism. Insiders signaled strong conviction early in 2025, with the CEO, CFO, and several directors buying shares. However, those purchases preceded clinical trial results showing the lead candidate did not meet intended endpoints. There remains some hope: another trial is underway but is not expected to report until H2 2026 at the earliest. Analysts have cut price targets and significantly reduced upside expectations following the failed trial. 
|
No comments:
Post a Comment
Keep a civil tongue.